tldrdaily.news logo

FDA Approves Precigen's Immunotherapy for Rare Respiratory Tumors and RRP

1 min read
Source: fda.gov
FDA Approves Precigen's Immunotherapy for Rare Respiratory Tumors and RRP
Photo: fda.gov
TL;DR Summary

The FDA has approved Papzimeos, a novel immunotherapy for adult recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV 6 or 11, offering a potential alternative to repeated surgeries with durable responses observed in clinical trials.

Topics:business#fda-approval#health#hpv#immunotherapy#papzimeos#recurrent-respiratory-papillomatosis
Share this article
  1. FDA Approves First Immunotherapy for Recurrent Respiratory Papillomatosis  fda.gov
  2. Precigen stock up on FDA nod for gene therapy (PGEN:NASDAQ)  Seeking Alpha
  3. FDA okays Precigen's immunotherapy for rare respiratory benign tumours  FirstWord Pharma
  4. First-Ever Treatment for 27,000 RRP Patients: Precigen's PAPZIMEOS Eliminates Surgery Need in 51% of Cases  Stock Titan
  5. FDA clears Precigen's rare tumour immunotherapy  pharmaphorum

Reading Insights

Total Reads

0

Unique Readers

2

Time Saved

2 min

vs 3 min read

Condensed

93%

512 → 37 words

Want the full story? Read the original article

Read on fda.gov